New hope for kids with rare kidney disease: drug aims to cut protein leak
NCT ID NCT06994845
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 26 times
Summary
This study tests an oral drug called iptacopan in 31 children aged 2 to under 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug reduces protein in the urine, a sign of kidney damage, and to check its safety. Participants take the drug for several months and have regular blood and urine tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Childrens Hospital Colorado
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Childrens Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104-4399, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Novartis Investigative Site
RECRUITINGBrisbane, Queensland, 4101, Australia
-
Novartis Investigative Site
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Novartis Investigative Site
RECRUITINGHangzhou, Zhejiang, 310052, China
-
Novartis Investigative Site
RECRUITINGBeijing, 100034, China
-
Novartis Investigative Site
RECRUITINGHong Kong, 999077, Hong Kong
-
Novartis Investigative Site
RECRUITINGBeersheba, 8457108, Israel
-
Novartis Investigative Site
RECRUITINGHaifa, 3109601, Israel
-
Novartis Investigative Site
RECRUITINGJerusalem, 9103102, Israel
-
Novartis Investigative Site
RECRUITINGPetah Tikva, 4920235, Israel
-
Novartis Investigative Site
RECRUITINGKurume, Fukuoka, 830-0011, Japan
-
Novartis Investigative Site
RECRUITINGOhtsu, Shiga, 5202192, Japan
-
Novartis Investigative Site
RECRUITINGFuchū, Tokyo, 1838561, Japan
-
Prim Childrens Hosp Inv Pharm
RECRUITINGSalt Lake City, Utah, 84113, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.